ABSTRACT
BACKGROUND & AIMS: Gastric cancer (GC) is a major cancer type characterized by high heterogeneity in both tumor cells and the tumor immune microenvironment (TIME). One intractable GC subtype is gastric signet-ring cell carcinoma (GSRCC), which is associated with poor prognosis. However, it remains unclear what the GSRCC TIME characteristics are and how these characteristics may contribute to clinical outcomes. METHODS: We enrolled 32 patients with advanced GC of diverse subtypes and profiled their TIME using an immune-targeted single-cell profiling strategy, including (1) immune-targeted single-cell RNA sequencing (n = 20 patients) and (2) protein expression profiling by a targeted antibody panel for mass cytometry (n = 12 patients). We also generated matched V(D)J (variable, diversity, and joining gene segments) sequencing of T and B cells along CD45+ immunocytes. RESULTS: We found that compared to non-GSRCC, the GSRCC TIME appears to be quiescent, where both CD4+ and CD8+ T cells are difficult to be mobilized, which further impairs the proper functions of B cells. CXCL13, mainly produced by follicular helper T cells, T helper type 17, and exhausted CD8+ T cells, is a central coordinator of this transformation. We show that CXCL13 expression can predict the response to immune checkpoint blockade in GC patients, which may be related to its effects on tertiary lymphoid structures. CONCLUSIONS: Our study provides a comprehensive molecular portrait of immune cell compositions and cell states in advanced GC patients, highlighting adaptive immune irresponsiveness in GSRCC and a mediator role of CXCL13 in TIME. Our targeted single-cell transcriptomic and proteomic profiling represents a powerful approach for TIME-oriented translational research.
Subject(s)
Carcinoma, Signet Ring Cell , Stomach Neoplasms , Humans , Stomach Neoplasms/genetics , CD8-Positive T-Lymphocytes , Proteomics , Carcinoma, Signet Ring Cell/genetics , Tumor MicroenvironmentABSTRACT
Heterogeneity and drug resistance of tumor cells are the leading causes of incurability and poor survival for patients with recurrent breast cancer. In order to accurately deliver the biological anticancer drugs to different subtypes of malignant tumor cells for omnidirectional targeted treatment of recurrent breast cancer, a distinct design is demonstrated by embedding liposome-based nanocomplexes containing pro-apoptotic peptide and survivin siRNA drugs (LPR) into Herceptin/hyaluronic acid cross-linked nanohydrogels (Herceptin-HA) to fabricate a HER2/CD44-targeted hydrogel nanobot (named as ALPR). ALPR delivered cargoes to the cells overexpressing CD44 and HER2, followed by Herceptin-HA biodegradation, subsequently, the exposed lipid component containing DOPE fused with the endosomal membrane and released peptide and siRNA into the cytoplasm. These experiments indicated that ALPR can specifically deliver Herceptin, peptide, and siRNA drugs to HER2-positive SKBR-3, triple-negative MDA-MB-231, and HER2-negative drug-resistant MCF-7 human breast cancer cells. ALPR completely inhibited the growth of heterogeneous breast tumors via multichannel synergistic effects: disrupting mitochondria, downregulating the survivin gene, and blocking HER2 receptors on the surface of HER2-positive cells. The present design overcomes the chemical drug resistance and opens a feasible route for the combinative treatment of recurrent breast cancer, even other solid tumors, utilizing different kinds of biological drugs.
Subject(s)
Breast Neoplasms , Humans , Female , Breast Neoplasms/metabolism , Survivin , Hydrogels , Trastuzumab/pharmacology , Trastuzumab/therapeutic use , RNA, Small Interfering , Cell Line, Tumor , Receptor, ErbB-2/genetics , Hyaluronan Receptors/metabolismABSTRACT
BACKGROUND: Particulate Matter (PM) is known to cause inflammatory responses in human. Although prior studies verified the immunogenicity of PM in cell lines and animal models, the effectors of PM exposure in the respiratory system and the regulators of the immunogenicity of PM is not fully elucidated. METHODS: To identify the potential effector of PM exposure in human respiratory system and to better understand the biology of the immunogenicity of PM, We performed gene-expression profiling of peripheral blood mononuclear cells from 171 heathy subjects in northern China to identify co-expressed gene modules associated with PM exposure. We inferred transcription factors regulating the co-expression and validated the association to T-cell differentiation in both primary T-cells and mice treated with PM. RESULTS: We report two transcription factors, IRF4 and STAT3, as regulators of the gene expression in response to PM exposure in human. We confirmed that the activation of IRF4 and STAT3 by PM is strongly associated with imbalanced differentiation of T-cells in the respiratory tracts in a time-sensitive manner in mouse. We also verified the consequential inflammatory responses of the PM exposure. Moreover, we show that the protein levels of phosphorylated IRF4 and STAT3 increase with PM exposure. CONCLUSIONS: Our study suggests the regulatory activities of IRF4 and STAT3 are associated with the Th17-mediated inflammatory responses to PM exposure in the respiratory tracts, which informs the biological background of the immunogenicity of particulate matters.
Subject(s)
Cell Differentiation/physiology , Interferon Regulatory Factors/biosynthesis , Particulate Matter/administration & dosage , STAT3 Transcription Factor/biosynthesis , Th17 Cells/metabolism , Administration, Inhalation , Adult , Aged , Aged, 80 and over , Animals , Cell Differentiation/drug effects , China/epidemiology , Female , Humans , Interferon Regulatory Factors/genetics , Male , Mice , Mice, Inbred BALB C , Middle Aged , Particulate Matter/adverse effects , STAT3 Transcription Factor/genetics , T-Lymphocytes/drug effects , T-Lymphocytes/metabolism , Th17 Cells/drug effects , Young AdultABSTRACT
We examined how Raoultella ornithinolytica-ZK4 degraded pyrethroid pesticides within soil sediment from an abandoned pesticide plant. Lambda-cypermethrin and deltamethrin are two pyrethroid insecticides with high insecticidal activity and a wide range of applications. However, their increased use has raised concerns regarding toxicity and accumulation. We isolated a strain of ZK4 (Raoultella ornithinolytica-ZK4) from soil taken from a channel that surrounded a pesticide plant. We used enzyme localization to study degrading bacteria ZK4. The ZK4 strain underwent intracellular enzyme degradation. The degradation rates of lambda-cyhalothrin and deltamethrin were 55% and 53%, respectively. The optimum pH of the two kinds of pyrethroids in ZK4 was 6.5, and their optimum temperature was 37 °C. The intracellular degradation of the crude enzyme produced by the ZK4 strain had a pH of 6.0-8.0 and a temperature of 20-42 °C. The ZK4 strain genome contained 5310 genes with a total length of 4,864,494 bp. Sugar metabolism and exogenous chemical metabolism accounted for the largest proportion of metabolic activities. We used the clusters of orthologous groups (COG) alignment and found numbers for 4686 protein sequences, accounting for 88.25% of the total predicted protein. ZK4 degraded lambda-cyhalothrin and deltamethrin, and may serve as a reference for the preparation of future degrading microbial agents to assist with environmental restoration efforts.
Subject(s)
Biodegradation, Environmental , Enterobacteriaceae/metabolism , Insecticides/metabolism , Soil Pollutants/metabolism , Soil/chemistry , Enterobacteriaceae/genetics , Enterobacteriaceae/isolation & purification , Nitriles/metabolism , Pyrethrins/metabolism , TemperatureABSTRACT
Deltamethrin is a pyrethroid insecticide with high insecticidal activity and a wide range of applications. However, with the increased amount and scope of its application, the accumulated toxicity of deltamethrin has gradually raised concerns. In this study, a bacterium strain, which used deltamethrin as its sole carbon source and was named ZJ6 (Lysinibacillus sp.-ZJ6), was isolated from soil samples collected from the sewage outlet of a pesticide plant in Tianjin. Based on morphological observations of ZJ6, as well as its physiological and biochemical characteristics and 16S rDNA sequence (Gen Bank Accession No. KU129013), the strain was identified as Lysinibacillus fusiformis sp.. A study of the degradation characteristics of ZJ6 revealed that the optimum conditions for shake flask fermentation to degrade deltamethrin by ZJ6 were as follows: pH 7.0, a temperature of 30 °C, a substrate concentration of 100-200 mg/L, an inoculation volume of 10%, and 7 days culturing at 160 rpm. Under these conditions, the degradation rate of deltamethrin by ZJ6 reached 57.2%. Preliminary sequencing of the ZJ6 genome showed that it has a total length of 3,921,852 bp and contains 4567 genes. The average length of each gene in the ZJ6 genome is 859 bp, and these genes account for 84.62% of the total genome length. KEGG metabolic pathway analysis revealed that genes involved in sugar metabolism and metabolism of exogenous chemical substances were significantly enriched in the genome of ZJ6. Comparison with the COG database showed that 2839 of the predicted protein sequences from the ZJ6 genome had COG numbers. Among all protein functions, the number of genes involved in general functions was the highest (372). For the first time, it was found that ZJ6 has relatively strong deltamethrin degradation ability and high value as a subject for further research. In addition, this study provides a reference to guide the preparation of pesticide-degrading bacterial agents and environmental remediation.
Subject(s)
Bacteria/isolation & purification , Bacteria/metabolism , Genome, Bacterial , Insecticides/metabolism , Nitriles/metabolism , Pyrethrins/metabolism , Sewage/microbiology , Bacteria/classification , Bacteria/genetics , Biodegradation, Environmental , Phylogeny , Sequence Analysis, DNA , TemperatureABSTRACT
Pulmonary fibrosis (PF) is one of the leading causes of death in systemic sclerosis (SSc) patients. Although all SSc patients are characterized by autoimmunity, only part of them suffer from PF, suggesting that beside autoimmunity, some additional factors are involved in the initiation of PF in SSc. In this study, we aimed to identify genetic polymorphisms associated with the status of PF in SSc. We performed that an exhaustive search of the PubMed database was performed to identify eligible studies. Then, a comprehensive meta-analysis was performed by comparing PF+-SSc and PF--SSc patients to identify genetic polymorphisms associated with the status of PF in SSc. Among eight SSc-associated susceptibility polymorphisms which were applied for meta-analysis, IRF5 rs2004640 polymorphism (OR 1.12; 95% CI 1.02-1.22, P = 1.39 × 10-2), STAT4 rs7574865 polymorphism (OR 1.25; 95% CI 1.07-1.47, P = 5.3 × 10-3), IRAK1 rs1059702 polymorphism (OR 1.20; 95% CI 1.05-1.37, P = 0.007), and CTGF G-945C polymorphism (OR 1.42; 95% CI 1.18-1.71, P = 0.002) are associated with PF status in SSc, while TNFAIP3 rs5029939, CD226 rs763361, CD247 rs2056626, and IRF5 rs10488631 polymorphisms are not. Since IRF5, STAT4, and IRAK1 are important regulatory factors in the control of innate immune responses and CTGF is involved in the synthesis of extracellular matrix, these results suggest a role of the innate immunity and matrix compounds in the pathogenesis of PF in SSc.
Subject(s)
Connective Tissue Growth Factor/genetics , Interferon Regulatory Factors/genetics , Interleukin-1 Receptor-Associated Kinases/genetics , Pulmonary Fibrosis/genetics , STAT4 Transcription Factor/genetics , Scleroderma, Systemic/genetics , Case-Control Studies , Genetic Markers , Genetic Predisposition to Disease , Genotype , Humans , Polymorphism, Single Nucleotide , Scleroderma, Systemic/complicationsABSTRACT
Cetuximab (Cet) and oxaliplatin (OXA) are used as first-line drugs for patients with colorectal carcinoma (CRC). In fact, the heterogeneity of CRC, mainly caused by K-ras mutations and drug resistance, undermines the effectiveness of drugs. Recently, a hydrophobic prodrug, (1E,4E)-6-((S)-1-(isopentyloxy)-4-methylpent-3-en-1-yl)-5,8-dimethoxynaphthalene-1,4dione dioxime (DMAKO-20), has been shown to undergo tumor-specific CYP1B1-catalyzed bioactivation. This process results in the production of nitric oxide and active naphthoquinone mono-oximes, which exhibit specific antitumor activity against drug-resistant CRC. In this study, a Cet-conjugated bioresponsive DMAKO-20/PCL-PEOz-targeted nanocodelivery system (DMAKO@PCL-PEOz-Cet) was constructed to address the issue of DMAKO-20 dissolution and achieve multitargeted delivery of the cargoes to different subtypes of CRC cells to overcome K-ras mutations and drug resistance in CRC. The experimental results demonstrated that DMAKO@PCL-PEOz-Cet efficiently delivered DMAKO-20 to both K-ras mutant and wild-type CRC cells by targeting the epidermal growth factor receptor (EGFR). It exhibited a higher anticancer effect than OXA in K-ras mutant cells and drug-resistant cells. Additionally, it was observed that DMAKO@PCL-PEOz-Cet reduced the expression of glutathione peroxidase 4 (GPX4) in CRC cells and significantly inhibited the growth of heterogeneous HCT-116 subcutaneous tumors and patient-derived tumor xenografts (PDX) model tumors. This work provides a new strategy for the development of safe and effective approaches for treating CRC. STATEMENT OF SIGNIFICANCE: (1) Significance: This work reports a new approach for the treatment of colorectal carcinoma (CRC) using the bioresponsible Cet-conjugated PCL-PEOz/DMAKO-20 nanodelivery system (DMAKO@PCL-PEOz-Cet) prepared with Cet and PCL-PEOz for the targeted transfer of DMAKO-20, which is an anticancer multitarget drug that can even prevent drug resistance, to wild-type and K-ras mutant CRC cells. DMAKO@PCL-PEOz-Cet, in the form of nanocrystal micelles, maintained stability in peripheral blood and efficiently transported DMAKO-20 to various subtypes of colorectal carcinoma cells, overcoming the challenges posed by K-ras mutations and drug resistance. The system's secure and effective delivery capabilities have also been confirmed in organoid and PDX models. (2) This is the first report demonstrating that this approach simultaneously overcomes the K-ras mutation and drug resistance of CRC.
Subject(s)
Antineoplastic Agents , Colorectal Neoplasms , Humans , Cetuximab/pharmacology , Cetuximab/therapeutic use , Nanoparticle Drug Delivery System , Cell Line, Tumor , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Colorectal Neoplasms/drug therapy , Colorectal Neoplasms/genetics , Colorectal Neoplasms/pathology , Oxaliplatin/pharmacology , Oxaliplatin/therapeutic use , Drug Resistance, Neoplasm , Mutation , Hydrogen-Ion ConcentrationABSTRACT
Regulatory T (Treg) cells play a critical regulatory role in the immune system by suppressing excessive immune responses and maintaining immune balance. The effective migration of Treg cells is crucial for controlling the development and progression of inflammatory diseases. However, the mechanisms responsible for directing Treg cells into the inflammatory tissue remain incompletely elucidated. In this study, we identified BAF60b, a subunit of switch/sucrose nonfermentable (SWI/SNF) chromatin remodeling complexes, as a positive regulator of Treg cell migration that inhibits the progression of inflammation in experimental autoimmune encephalomyelitis (EAE) and colitis animal models. Mechanistically, transcriptome and genome-wide chromatin-landscaped analyses demonstrated that BAF60b interacts with the transcription factor RUNX1 to promote the expression of CCR9 on Treg cells, which in turn affects their ability to migrate to inflammatory tissues. Our work provides insights into the essential role of BAF60b in regulating Treg cell migration and its impact on inflammatory diseases.
Subject(s)
Cell Movement , Inflammation , Mice, Inbred C57BL , T-Lymphocytes, Regulatory , T-Lymphocytes, Regulatory/immunology , T-Lymphocytes, Regulatory/metabolism , Animals , Mice , Inflammation/pathology , Inflammation/metabolism , Chromatin Assembly and Disassembly , Chromosomal Proteins, Non-Histone/metabolism , Encephalomyelitis, Autoimmune, Experimental/immunology , Encephalomyelitis, Autoimmune, Experimental/pathology , Encephalomyelitis, Autoimmune, Experimental/metabolism , Encephalomyelitis, Autoimmune, Experimental/genetics , Humans , Transcription Factors/metabolism , Core Binding Factor Alpha 2 Subunit/metabolism , Core Binding Factor Alpha 2 Subunit/genetics , Colitis/metabolism , Colitis/pathology , Colitis/immunology , Colitis/geneticsABSTRACT
Breast cancer (BC) is the most common malignancy in women worldwide, and it is a molecularly diverse disease. Heterogeneity can be observed in a wide range of cell types with varying morphologies and behaviors. Molecular classifications are broadly used in clinical diagnosis, including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), and breast cancer gene (BRCA) mutations, as indicators of tumor heterogeneity. Treatment strategies differ according to the molecular subtype. Besides the traditional treatments, such as hormone (endocrine) therapy, radiotherapy, and chemotherapy, innovative approaches have accelerated BC treatments, which contain targeted therapies and immunotherapy. Among them, monoclonal antibodies, small-molecule inhibitors and antibody-drug conjugates, and targeted delivery systems are promising armamentarium for breast cancer, while checkpoint inhibitors, CAR T cell therapy, cancer vaccines, and tumor-microenvironment-targeted therapy provide a more comprehensive understanding of breast cancer and could assist in developing new therapeutic strategies.
ABSTRACT
Innate lymphoid cells (ILCs) have been identified as a heterogeneous population of lymphocytes that mirrors the cytokine and transcriptional profile of adaptive T cells. The dynamic balance between key transcription factors determines the heterogeneity, plasticity, and functions of ILC subsets. The transcription factor ThPOK is highly conserved in biological evolution and exerts pivotal functions in the differentiation of T cells. However, the function of ThPOK in ILC3s has not been identified. Here, we found that ThPOK regulated the homeostasis of ILC3s, as mice lacking ThPOK showed decreased NKp46+ ILC3s and increased CCR6- NKp46- ILC3s. ThPOK-deficient mice were more sensitive to S. typhimurium infection due to the impaired IFN-γ secretion of NKp46+ ILC3s. Furthermore, ThPOK participates in ILC3-mediated control of C. rodentium infection by negatively regulating IL-17A secretion. ThPOK preserves the identity of NKp46+ ILC3s by repressing RORγt, which indirectly releases T-bet expression. On the molecular level, ThPOK directly binds to Rorc and Il23r to restrain their expression which further modulates IL-17A secretion. Collectively, our analysis revealed a critical role of ThPOK in the homeostasis and functions of ILC3 subsets.
Subject(s)
Interleukin-17 , Lymphocytes , Transcription Factors , Animals , Homeostasis , Immunity, Innate , Interleukin-17/metabolism , Lymphocytes/metabolism , Mice , Transcription Factors/metabolismABSTRACT
Mucus produced by goblet cells in the gastrointestinal tract forms a biological barrier that protects the intestine from invasion by commensals and pathogens. However, the host-derived regulatory network that controls mucus secretion and thereby changes gut microbiota has not been well studied. Here, we identify that Forkhead box protein O1 (Foxo1) regulates mucus secretion by goblet cells and determines intestinal homeostasis. Loss of Foxo1 in intestinal epithelial cells (IECs) results in defects in goblet cell autophagy and mucus secretion, leading to an impaired gut microenvironment and dysbiosis. Subsequently, due to changes in microbiota and disruption in microbiome metabolites of short-chain fatty acids, Foxo1 deficiency results in altered organization of tight junction proteins and enhanced susceptibility to intestinal inflammation. Our study demonstrates that Foxo1 is crucial for IECs to establish commensalism and maintain intestinal barrier integrity by regulating goblet cell function.
Subject(s)
Forkhead Box Protein O1/metabolism , Gastrointestinal Microbiome/physiology , Gastrointestinal Tract/physiology , Mucus/metabolism , Animals , Autophagy/physiology , Colitis/chemically induced , Colitis/metabolism , Colitis/microbiology , Dysbiosis/genetics , Fatty Acids, Volatile/metabolism , Female , Forkhead Box Protein O1/genetics , Goblet Cells/pathology , Intestinal Mucosa/cytology , Intestinal Mucosa/metabolism , Intestinal Mucosa/microbiology , Male , Mice, Inbred C57BL , Mucin-2/metabolism , Symbiosis/physiologyABSTRACT
BACKGROUND: Small cell lung cancer (SCLC) is one of the deadliest malignancies and accounts for nearly 15% of lung cancers. Previous study had revealed the genomic characterization of SCLC in Western patients. However, little is known about that in Chinese SCLC patients. METHODS: Formalin-fixed paraffin-embedded tumor tissues and matched blood samples from 122 Chinese SCLC patients were collected for next generation sequencing to detect 450 cancer-related genes. All pathological diagnoses were confirmed by independent pathologists. RESULTS: The most frequently altered genes were TP53 (93.4%), RB1 (78.7%), LRP1B (18.9%), KMT2D (15.6%), FAT1 (11.5%), KMT2C (11.5%), SPTA1 (11.5%), STK24 (11.5%), FAM135B (10.7%), and NOTCH1 (10.7%). The gene fusion/rearrangement detection rate was 16.4%, and mostly occurred in chromosomes 7 and 17. The rate of co-occurring mutations of TP53 and RB1 in these Chinese SCLC patients was 74.6%, and lower than the reported Western patients (90.9%, P = 0.007). The most common gene mutations (83.6%) were found in cell cycle signaling pathway in Chinese SCLC patients. Mutation of Wnt and Notch signaling pathways in the Chinese cohort were lower than Western cohort (P = 0.0013 and 0.0068). A significant association was found between high tumor mutation burden and mutations involved in FAT1, TP53, SPTA1, KEAP1, KMT2D, MAGI2, NOTCH2, NOTCH3, FLT1, KDM6A, and FAT4. CONCLUSIONS: In this study, we characterized the genomic alterations profile of Chinese SCLC patients. Compared with westerners, the genetic alterations of Chinese SCLC patients presented different patterns. Our data might provide useful information in targeted therapy and drug development for Chinese SCLC patients.
Subject(s)
Asian People/genetics , Gene Regulatory Networks , High-Throughput Nucleotide Sequencing/methods , Lung Neoplasms/pathology , Small Cell Lung Carcinoma/pathology , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor/genetics , Cell Cycle , China , Female , Humans , Lung Neoplasms/genetics , Male , Middle Aged , Mutation , Sequence Analysis, DNA , Small Cell Lung Carcinoma/genetics , White People/genetics , Wnt Signaling PathwayABSTRACT
BACKGROUND: KRAS-mutant lung adenocarcinomas (LUADs) are heterogeneous and frequently occur in smokers. The heterogeneity of KRAS-mutant LUAD has been an obstacle for the drug discovery. METHODS: We integrated multiplatform datatypes and identified two corresponding subtypes in the patients and cell lines. We further characterized the features of these two subtypes and performed drug screening to identify subtype-specific drugs. Finally, we used the defining features of the KRAS subtypes for drug sensitivity prediction. FINDINGS: Patient-Subtype 1 (PS1) was characterized by increased smoking-related mutational signature activity, a low tumor-infiltrating lymphocyte (TIL)-associating score and STK11/KEAP1 co-mutations. Patient-Subtype 2 (PS2) was characterized by an increased smoking-related methylation signature activity, a high TIL-associating score and increased KRAS dependency. The cell line subtypes faithfully recapitulated all the patients' features. Drug screening of the two cell line subtypes yielded several potential candidates, such as cytarabine and enzastaurin for Cell-line-Subtype 1 (CS1) and a BTK inhibitor QL-XII-61 for Cell-line-Subtype 2 (CS2). The defining features, such as smoking-related methylation signature, were significantly associated with the sensitivity to several drugs. INTERPRETATION: The heterogeneity of KRAS-mutant LUAD is associated with smoking-related genomic and epigenomic aberration along with other features such as immunogenicity, KRAS dependency and STK11/KEAP1 co-mutations. These features might be used as biomarkers for drug sensitivity prediction. FUND: This research was funded by the Young Scientists Fund of the National Natural Science Foundation of China, the Natural Science Foundation of Fujian Province, China and the Education and Research Foundation for Young Scholars of Education Department of Fujian Province, China.
Subject(s)
Adenocarcinoma of Lung/diagnosis , Adenocarcinoma of Lung/genetics , Biomarkers, Tumor , Mutation , Proto-Oncogene Proteins p21(ras)/genetics , Adenocarcinoma of Lung/drug therapy , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Cell Line, Tumor , DNA Copy Number Variations , DNA Methylation , Drug Resistance, Neoplasm , Female , Gene Expression Profiling , Humans , Lymphocytes, Tumor-Infiltrating/immunology , Lymphocytes, Tumor-Infiltrating/metabolism , Lymphocytes, Tumor-Infiltrating/pathology , Male , Molecular Targeted Therapy , PrognosisABSTRACT
The normal Raman spectrum (RRS) of solanesol molecules and surface enhanced raman scattering (SERS) of these molecules adsorbted on Pt electrode surface are reported in this paper. By comparison that the results show that the molecules of solanesol is adsorbed on the Pt surface through the C=C bond. The large difference between RRS and SERS demonstrates that the interaction between the molecules and Pt surface is rather strong and this interaction leads to a large disturbance to the molecules structure of solanesol.
Subject(s)
Electrodes , Platinum , Terpenes/chemistry , Adsorption , Molecular Structure , Scattering, Radiation , Spectrum Analysis, Raman/methodsABSTRACT
OBJECTIVE: A disintegrin and metalloprotease (ADAM)10 has been implicated in the progression of various solid tumours. Little is known, however, about its role in hepatocellular carcinoma (HCC). The aim of the present study was to evaluate the protein and transcript level expression of ADAM10 in HCC patients. METHODS: Samples of HCC and adjacent noncancerous liver tissue were taken during liver resection surgery. Immunostaining was used to measure ADAM10 protein expression levels and quantitative reverse- transcription polymerase chain reaction was used to measure ADAM10 mRNA expression levels. Levels of ADAM10 were compared, and a survival analysis undertaken. RESULTS: In total, 98 HCC patient samples were studied. There were significant associations between protein levels of ADAM10 and tumour grade, amount of tumour differentiation, tumour size and the presence of metastasis. Furthermore, ADAM10 protein expression was significantly associated with shortened patient survival. CONCLUSIONS: ADAM10 is strongly expressed in a large proportion of HCC cases, which is in agreement with findings in other tumour entities. Expression of ADAM10 may serve as a useful molecular marker for HCC.